研發策略 Strategy

百靈佳殷格翰的研發策略旨在進一步提高我們的創新能力，並激發更多解決疾病問題的創新。

四大治療研究領域
在藥品與解決方案的各階段，如從早期研究推展到臨床試驗，再到市場進入…等，透過持續關注已累積專業知識的疾病類別來強化研發優勢。

創造並提供研發平台
專注於高度動態發展的研究領域，如免疫調節和再生醫學，藉此引動我們的幾個研究治療領域間的協同作用。

無限際研發
探索新興科學技術，跨越現有研究治療範疇，以便即時並有效地進入全新的醫療和科學領域與技術。

Our new discovery research strategy aims at further enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need. It is based on three pillars:

Four Discovery Research Therapeutic Areas
Build on our strengths in R&D by focusing on core diseases for which we have built expertise over time and are actively investing from early research, through clinical development, to the market phase.

Scientific platforms
Focus on highly dynamic research fields such as immune modulation and regenerative medicine which may impact and create synergies among several of our Discovery Research Therapeutic Areas.

Research Beyond Borders
Explore emerging science and technology for but also beyond our Discovery Research Therapeutic Areas in order to prepare a timely and efficient entry into emerging new medical and scientific fields and technologies.


心臟代謝疾病研究 Cardiometabolic Diseases Research

我們的研發近年來取得了許多重要的成果，特別是血栓栓塞性疾病和第2型糖尿病。 目前的研究重點專注在治療糖尿病、肥胖、非酒精性脂肪性肝炎（NASH）、糖尿病性視網膜病變和慢性腎臟疾病的新對策。這些治療方法間彼此相輔相成，進而得以降低心血管死亡率和發病率。目前約有300名科學家在德國比貝拉和美國康乃狄克州的里奇菲爾德藥物研發中心全力投入我們的心臟代謝研究。

 

 

我們研發的重點是:
 

  • 第2型糖尿病
  • 糖尿病的血管病變，如：糖尿病性視網膜病變，糖尿病性腎病，慢性腎臟疾病，心血管連動病變
  • 肝部疾病 ，如：NASH
  • 肥胖

Our research and development has resulted in important achievements in recent years, especially in thromboembolic diseases and type 2 diabetes. Our current research efforts focus on new strategies for the treatment of diabetes, obesity, non-alcoholic Steatohepatitis (NASH), diabetic retinopathy, and chronic kidney disease. Together these therapies complement each other to reduce the risk of cardiovascular mortality and morbidity. Around 300 scientists work in our fully integrated drug discovery centre of excellence for Cardiometabolic research at sites in Biberach, Germany and Ridgefield, CT, USA

 

Our Discovery Research focus is on:
 

  • Type 2 diabetes
  • Micro- and macrovascular complications of diabetes – e.g. diabetic retinopathy, diabetic nephropathy, chronic kidney diseases, CV outcomes
  • Liver diseases – e.g. NASH
  • Obesity